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Abstract
Replication Protein A (RPA) is an essential single-stranded DNA (ssDNA) binding protein that 
initiates the DNA damage response pathway through protein-protein interactions (PPIs) mediated 
by its 70N domain. The identification and use of chemical probes that can specifically disrupt 
these interactions is important for validating RPA as a cancer target. A high throughput screen 
(HTS) to identify new chemical entities was conducted and identified 90 hit compounds. From 
these initial hits, an anthranilic acid-based series was optimized using a structure-guided iterative 
medicinal chemistry approach to yield a cell penetrant compound that binds to RPA70N with an 
affinity of 812 nM. This compound (20c) is capable of inhibiting protein-protein interactions 
mediated by this domain.
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Introduction
Replication Protein A (RPA), the primary single strand DNA (ssDNA) binding protein in 
eukaryotes, is essential for DNA replication, damage response and repair. In addition to 
binding to and protecting ssDNA from degradation, RPA recruits partner proteins involved 
in these processes. RPA is comprised of three subunits, each bearing OB-fold domains.1,2 
The N-terminal domain of the 70-kDa subunit (RPA70N) is one of two key sites that 
mediates the recruitment of partner proteins.3 This domain is particularly important for the 
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recruitment of DNA damage response proteins to sites of DNA damage via interaction with 
the RPA70N central basic cleft.3–6
Based on the key role of RPA70N-mediated protein-protein interactions (PPIs) in initiating 
the DNA damage response, it is possible that specific inhibition of this RPA function may 
represent an attractive pathway for therapeutic intervention in cancer. We and others are 
pursuing inhibitors of the RPA70N-mediated PPIs that do not interfere with the ability of 
RPA to bind to and protect ssDNA, as these would allow for further exploration of the role 
of RPA in checkpoint signaling, enable studies to confirm the therapeutic potential of RPA 
inhibition, and serve as a potential starting point for new cancer drugs.
Based on this unique opportunity for small molecule inhibitors of RPA as potential cancer 
therapeutics, research on RPA inhibitors has intensified over the last several years. Turchi 
and colleagues have identified dihydropyrazole 1 (Figure 1), which binds to a DNA-binding 
domain of RPA and disrupts its interaction with ssDNA.7,8 Oakley and colleagues identified 
fumaropimaric acid (2; Figure 1), which was shown to disrupt both RPA70N-Rad9 and 
RPA70N-p53 interactions.9,10 The Oakley laboratory has also reported on HAMNO (3, 
Figure 1), which was shown to inhibit RPA binding to RAD9 and cause increased replicative 
stress and cytotoxicity in cancer cells and slowed the progression of squamous cell 
carcinoma in a xenograft model.11
We have previously reported on the results of an NMR-based fragment screen to identify 
novel molecules that bind to RPA70N. This screen revealed several distinct chemotypes of 
fragments that bind to the domain. Remarkably, this single screen identified two distinct 
binding locations in the basic cleft of RPA70N (Site-1 and Site-2) which can be 
independently and simultaneously occupied by two different compounds.12,13 From these 
results, we have also described the results of two optimization campaigns. Initially a 
fragment merging strategy was employed, resulting in triazole 4 (Figure 1), which bound to 
only one site in the basic cleft.12 We have also described the results of a fragment linking 
strategy to generate compounds that span the entire cleft and incorporate features of two 
distinct fragment hits (5, Figure 1).13 Here, we describe a different class of molecules that 
was identified using a high throughput screen (HTS) and further optimized using iterative 
medicinal chemistry and structure-based design.
Results and Discussion
Using a previously reported fluorescence polarization anisotropy (FPA) screening assay, 
90,000 compounds from the Vanderbilt collection were screened at a single concentration of 
30 µM for their ability to disrupt the binding of a fluorescently labeled ATRIP-derived probe 
to RPA70N.14 This screen identified 674 compounds that displaced >10% of the probe from 
RPA70N at this concentration. These initial hits were further filtered to remove compounds 
that exhibited fluorescence interference and were prioritized for follow-up on the basis of the 
lack of potentially reactive chemical functionality and concordance with commonly accepted 
measures of drug-likeness.15,16 After this analysis, concentration response curves were 
collected for 90 compounds to determine IC50 values from which Kd values were calculated. 
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Of these 90 compounds, 52 were identified with a Kd less than 100 µM. Several of the most 
potent hits are depicted in Figure 2.3–6
Compound 6, with the highest ligand efficiency amongst the hit set, was briefly investigated. 
The results from this work were reported previously.17 Because of the high lipophilicity of 
the series and generally flat SAR, further work on the series was halted. Notably, Turchi and 
coworkers previously described a series of inhibitors of the interaction of RPA and ssDNA 
with a chemical structure similar to compound 9.17 Compounds 7 and 8 were of relatively 
low interest. Compounds 10 and 11 are similar and together form an anthranilic acid-based 
series. SAR evident in the HTS hit set indicated the nitro group was essential for binding of 
ether-based exemplars such as 10. Because of this, as well as the reasonably favorable 
combination of potency, ligand efficiency (LE), and the prospect of a modular synthetic 
route, we focused follow-up efforts onto sulfonamide variants such as compound 11.
To guide the optimization of 11, a co-crystal structure of compound 11 in complex with 
RPA70N was obtained (Figure 3). The binding mode of compound 11 shares several 
important contacts with the binding mode of the p53 peptide and our previously reported 
molecules. The 4-bromophenyl portion of the molecule occupies the hydrophobic Site-1 
pocket (Figure 3A), but lies flat against the surface of RPA70N and sits in a much more 
shallow position as compared to compounds 4 and 5 (Figure 3C). The sulfonamide of the 
molecule appears to establish the proper geometry necessary to orient the 4-bromophenyl 
into Site-1. The middle phenyl ring occupies the center of the RPA70N cleft and overlays 
well with the indole moiety of the tryptophan of the p53 peptide18 (Figure 3B) or the 
phenylalanine of a previously reported ATRIP-derived peptide19. The carboxylic acid of the 
anthranilic acid portion of the molecule engages in a charge-charge interaction with Arg41 
of RPA70N, a common interaction amongst our fragments and linked small molecule 
inhibitors of RPA70N. In addition, compound 11 also makes a unique H bond interaction to 
Asn85 of RPA70N using the carbonyl oxygen of the amide bond. We hypothesized the 
amide in this molecule was important due to both this interaction with RPA and its ability to 
form an internal H bond with the anthranilic acid of the molecule, thus maintaining the 
planarity of the molecule in its binding pose.
Based upon the binding mode of hit molecule 11 and our previous knowledge of small 
molecules binding to RPA70N, we devised a strategy to improve potency by optimizing the 
hydrophobic interactions of each of the phenyl rings while maintaining the hydrophilic 
interactions of the amide and carboxylic acid of the molecule. The first goal was to optimize 
the phenyl sulfonamide portion of the molecule for binding to the hydrophobic pocket of 
Site-1. An initial compound library containing various phenyl substituents and phenyl 
replacements was constructed, using a combination of chemical synthesis and analog 
purchases. Despite the majority of the analogs being less potent than the original hit, this 
library provided important SAR insights (Table 1).
Analogs bearing a 3-Cl or 4-Cl (18, 19) were equipotent with 11, while non-halogen 
substituents such as 3-Me, 4-Me, or 4-OMe (13, 14, or 15) were 5–8 fold less potent. In 
concordance with previously described SAR, analog 20 (3,4-diCl) displayed the best binding 
affinity of the initial set, showing a 4-fold improvement over 11. Both of the chlorine atoms 
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were necessary, as replacing either or both with a methyl group (21–23) reduced binding 
affinity by 6–20 fold compared with 20. Methylation of the sulfonamide was not tolerated, 
as all methylated analogs were 2–5 fold less potent than the des-methyl analogs (data not 
shown). Replacement of the phenyl ring with saturated ring systems (27–32, 34, and 35) in 
attempts to increase the hydrophobic interactions and increase the sp3 character of the 
molecule, were unsuccessful, as all analogs were 2–10 fold lower in binding affinity to 
RPA70N. Surprisingly, the 3,4-diCl substituted biphenyl 25 had an affinity of 4 µM, despite 
its increased size within Site-1. However, derivatives of this molecule were not pursued 
further due to poor LE (0.20) and cLogP (6.08), as well as potential solubility limitations.
To explore the SAR around the phenyl ring of the anthranilic acid portion of the molecule, a 
library of analogs was synthesized with varying R2 substituents, while R1 was fixed as either 
3,4-diCl, 3-Cl, or 4-Br. From this library, several clear SAR tends emerged (Table 2). 
Halogen R2 options were more beneficial at the 4-position, as compared to the 5-position, 
leading to an improvement of 2–10 fold. This observation can be rationalized from the co-
crystal structure, in which one can envision the 5-position substitution clashing with the lip 
of the cleft, whereas the 4-position substitution is oriented towards a hydrophobic gap. A 5-
Cl substitution at R2 consistently led to poor physicochemical properties, such as limiting 
solubility, as evidenced by precipitation under the assay conditions.
The most effective option at R2 for all three different R1 substitutions was replacement of 
the anthranilic acid phenyl ring with a naphthyl moiety (11l, 18l, 20l). These analogs 
displayed binding affinities of 1–4 µM. Based on the co-crystal structure of 11, the naphthyl 
substitution most likely occupies the hydrophobic space adjacent to both the 4- and 5-
positions. The analog with the best binding affinity (20c), however, contained a 3,4-diCl R1 
substitution and a 4-Br R2 substitution. This analog was slightly superior to the R2 = 
naphthyl analog (20l) and had a more attractive LE (0.27 compared to 0.24 for 20l). Further, 
compound 20c represents the best binding affinity yet observed for a molecule with only one 
acidic moiety.
The final strategy to optimize compound 11 was exploration of several substituents at R3 on 
the middle phenyl ring. However, several planned analogs (R3 = Cl, Br, or OMe, for 
example) were synthetically intractable, since intermediates required for the synthesis of 
these molecules were unstable under the conditions necessary for sulfonamide formation or 
saponification. Despite these challenges, several alkyl analogs were obtained (Table 3). The 
des-methyl analog 20m was 2-fold less potent than compound 20. Further extension of the 
methyl to an ethyl (20n) or isopropyl group (20o) showed marginal improvements in affinity 
(Kd = 4 and 5 µM, respectively). However, this slight gain in potency was offset by a 
decrease in solubility of these analogs, with both 20n and 20o showing some evidence of 
precipitation at the highest concentrations under the assay conditions.
Using a standard fluorescence-based DNA binding assay, we established that compound 20c 
does not affect ssDNA binding to RPA; the Kd value for ssDNA binding to RPA70AB in the 
RPA70NAB construct was the same in the absence and presence of the compound. Thus, 
20c appears to bind selectively to the RPA70N domain. Further, compound 20c was taken 
forward for characterization in cellular studies. The molecule was found to possess very high 
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protein binding (99.8%), but also exhibits high permeability (Papp A–B value of 29.2 × 10−6 
cm/sec in the Caco-2 line) relative to our previously reported compounds. Studies to define 
the cellular activity of this compound are underway and will be reported in due course.
Chemistry
The synthesis of the anthranilic acid-based inhibitors 11–36 utilized a modular route, 
allowing for the introduction of diversity at each step and only one chromatographic 
purification.21 The synthesis begins with an aromatic sulfonylation, upon treating a para-
substituted benzoic with chlorosulfonic acid. The carboxylic acid (40–42) is converted to an 
acid chloride and the methyl ester of the appropriate anthranilic acid is added to afford 
sulfonyl chlorides in greater than 90% yield. After a water work up, the final substituted 
phenyl ring is added to the sulfonyl chloride by the addition of the appropriate substituted 
aniline. This is followed by saponification of the methyl ester to yield the desired analog.
Conclusions
We have conducted a high throughput screen and initial compound optimization towards the 
discovery of new and selective chemical probes to validate inhibition of the protein-protein 
interactions mediated by RPA70N. Inhibitor 11 was initially identified as an attractive 
starting point for structure-based optimization. Subsequent optimization using an iterative 
medicinal chemistry process and structure-based design principles led to the discovery of 
20c, which binds to RPA70N with an affinity of 812 nM and displays adequate permeability 
and solubility characteristics for use in cellular studies.
Experimental Section
Chemistry
General Methods—All chemicals, reagents, and solvents were used as purchased from 
commercial sources, without further purification. All NMR spectra were recorded at room 
temperature on a 400 MHz Bruker spectrometer with a DRX-400 console, a 500 MHz 
Bruker spectrometer with a DRX-500 console, or a 600 MHz Bruker spectrometer with an 
AV-II console. 1H chemical shifts are reported in δ values in ppm downfield with the 
deuterated solvent as the internal standard. Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet, ovlp 
= overlap), coupling constant (Hz), and integration. Low-resolution mass spectra were 
obtained on an Agilent 1200 series 6140 mass spectrometer with electrospray ionization. All 
samples were of ≥90% purity as analyzed by LC−UV/vis−MS. Analytical HPLC was 
performed on an Agilent 1200 series with UV detection at 214 and 254 nm along with 
ELSD detection. LC−MS parameters were as follows: Phenomenex-C18 Kinetex column, 50 
mm × 2.1 mm, 2 min gradient, 5% to 100% (H2O/MeCN with 0.1% TFA). Preparative 
purification was performed on a Gilson HPLC (Phenomenex-C18, 100 mm × 30 mm, 10 
min gradient, (H2O/MeCN with 0.1% TFA) or by automated flash column chromatography 
(Teledyne Isco, Inc. Combiflash Rf).
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General Procedure for anthranilic acid-based inhibitors
The anthanilic-based inhibitors 11a–l, 12–17, 18a–l, 19, 20a–p, and 21–36 were prepared 
by the similar procedures. This procedure is exemplified for compound 11.18
3-(Chlorosulfonyl)-4-methylbenzoic acid 40—4-methylbenzoic acid 37 (1.0 g, 7.35 
mmol, 1 eq) was dissolved in chlorosulfonic acid (10 mL). The reaction was heated t reflux 
and stirred overnight. The next day, the reaction was cooled to room temperature and then 
poured onto ice. The solid was filtered, dissolved in DCM, and washed with 1M HCl. The 
DCM layer was then driesd (Na2SO4) and evaporated in vacuo to give the desired product 
37 (1.22 g, 71%). 1H-NMR (600 MHz, DMSO-d6): δ = 8.32 (d, J = 1.9 Hz, 1 H), 7.77 (dd, J 
= 2.0 Hz, 7.7 Hz, 1 H), 7.26 (d, J = 7.9 Hz, 1 H), 2.58 (s, 3H). 13C-NMR (125 MHz, DMSO-
d6): δ =167.2, 146.4, 141.2, 131.2, 129.6, 127.7, 127.5, 20.3. MS (ESI) [M + H]+ m/z = 
234.9.
Methyl 2-(3-(chlorosulfonyl)-4-methylbenzamido)benzoate 43a—The intermediate 
40 (235 mg, 1 mmol, 1 eq) was dissolved in thionyl chloride (4 mL). The reaction was 
heated to 75°C and stirred for 4 hours. Solvents were removed in vacuo. The resulting syrup 
was dissolved in toluene (3 × 5 mL) and evaporated. The product was taken forward without 
further purification.
The appropriate methyl-2-aminobenzoate (151 mg, 1 mmol, 1 eq) was dissolved in THF (4 
mL) and NaH (40 mg, 1 mmol, 1 eq) was added and stirred for 20 min. The acyl chloride (1 
mmol, 1 eq) was added and the reaction was stirred at rt for 2 hours. The reaction was 
diluted with DCM and washed with water. The DCM layer was dried (Na2SO4) and then 
evaporated in vacuo. The residue was taken forward without further purification (367 mg, 
quantitative). 1H-NMR (600 MHz, DMSO-d6): δ = 8.57 (dd, J = 0.8 Hz, 8.5 Hz, 1 H), 8.39 
(d, J = 2.1 Hz, 1 H), 8.00 (dt, J = 1.9 Hz, 8.0 Hz, 1 H), 7.80 (dd, J = 2.1 Hz, 7.8 Hz, 1 H), 
7.67 (m, 1 H), 7.37 (d, J = 7.9 Hz, 1 H), 7.22 (m, 1 H), 3.90 (s, 3 H), 2.62 (s, 3 H). 13C-
NMR (150 MHz, DMSO-d6): δ = 168.0, 164.7, 146.9, 140.5, 140.3, 134.3, 131.4, 131.1, 
130.8, 127.0, 125.7, 123.3, 120.9, 117.1, 52.7, 20.2. MS (ESI) [M + H]+ m/z = 368.0.
2-(3-(N-(4-bromophenyl)sulfamoyl)-4-methylbenzamido)benzoic acid 11—The 
sulfonyl chloride 43a (62 mg, 0.17 mmol, 1 eq) was dissolved in toluene (2 mL). The 4-
bromoaniline (86 mg, 0.5 mmol, 3 eq) is added and the rxn is stirred at 70°C overnight. The 
solvents were removed in vacuo. The resulting residue was dissolved in DCM and washed 
with water. The DCM layer was evaporated in vacuo and the residue was dissolved in THF 
(2 mL) and 2M LiOH (0.5 mL) was added. The reaction was stirred at 55°C for 2 hours. The 
reaction was neutralized with 2 M HCl (0.5 mL) and the solvents were removed in vacuo. 
The residue was purified via preparative HPLC to give the desired product (23 mg, 
28%). 1H-NMR (600 MHz, DMSO-d6): δ = 10.78 (s, 1 H), 8.67 (dd, J = 0.8 Hz, 8.4 Hz 1 
H), 8.52 (d, J = 1.9 Hz, 1 H), 8.08-8.05 (m, 2 H), 7.68 (m, 1 H), 7.62 (d, J = 8.1 Hz, 1 H), 
7.43-7.41 (m, 2 H), 7.24 (m, 1 H), 7.09-7.06 (m, 2 H), 3.39 (broad s, 1 H), 2.66 (s, 3 
H). 13C-NMR (150 MHz, DMSO-d6): δ = 170.6, 163.5, 141.6, 141.3, 138.3, 137.1, 134.9, 
134.1, 133.0, 132.7, 131.9, 131.8, 128.7, 123.8, 121.5, 120.5, 117.2, 116.2, 20.2. MS (ESI) 
[M + H]+ m/z = 489.1.
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Synthesized according to procedure for 11 in 42% yield. 1H-NMR (600 MHz, DMSO-d6): δ 
= 10.88 (s, 1 H), 8.67 (dd, J = 0.9 Hz, 8.4 Hz 1 H), 8.55 (d, J = 1.9 Hz, 1 H), 8.09-8.06 (m, 2 
H), 7.68 (m, 1 H), 7.63 (d, J = 8.1 Hz, 1 H), 7.27-7.23 (m, 2 H), 7.12-7.09 (m, 2H), 7.04 (m, 
1H), 3.40 (broad s, 1 H), 2.67 (s, 3 H). 13C-NMR (150 MHz, DMSO-d6): δ = 170.1, 162.9, 
141.2, 140.7, 138.8, 137.8, 134.4, 133.6, 133.5, 132.5, 132.4, 131.4, 131.3, 131.1, 128.2, 
123.4, 123.3, 120.0, 118.1, 116.9, 19.7. MS (ESI) [M + H]+ m/z = 445.2.
4-Bromo-2-(3-(N-(3-chlorophenyl)sulfamoyl)-4-methyl benzamido)benzoic acid 
18c—Synthesized according to procedure for 11 in 34% yield. 1H-NMR (600 MHz, 
DMSO-d6): δ = 10.91 (s, 1 H), 8.93 (d, J = 2.0 Hz 1 H), 8.55 (d, J = 2.0 Hz, 1 H), 8.06 (dd, J 
= 1.8 Hz, 7.4 Hz, 1 H), 7.99 (d, J = 8.4 Hz 1 H), 7.63 (d, J = 8.0 Hz, 1 H), 7.44 (dd, J = 2.0 
Hz, 8.6 Hz, 1 H), 7.27 (t, J = 8.1 Hz 1 H), 7.13-7.10 (m, 2 H), 7.05 (m, 1 H), 3.42 (broad s, 1 
H), 2.68 (s, 3 H). 13C-NMR (150 MHz, DMSO-d6): δ = 168.0, 161.5, 140.1, 139.8, 137.1, 
136.2, 132.1, 131.9, 131.3, 130.3, 129.8, 129.5, 126.6, 126.1, 124.5, 121.8, 120.6, 116.5, 
115.2, 114.2, 18.1. MS (ESI) [M + H]+ m/z = 568.9.
4-Bromo-2-(3-(N-(3,4-dichlorophenyl)sulfamoyl)-4-methyl benzamido)benzoic 
acid 20c—Synthesized according to procedure for 11 in 42% yield. 1H-NMR (600 MHz, 
DMSO-d6): δ = 11.05 (s, 1 H), 8.92 (d, J = 2.1 Hz 1 H), 8.53 (d, J = 1.9 Hz, 1 H), 8.06 (dd, J 
= 1.9 Hz, 7.9 Hz, 1 H), 7.98 (d, J = 8.5 Hz 1 H), 7.64 (d, J = 8.2 Hz, 1 H), 7.50 (d, J = 8.8 Hz 
1 H), 7.43 (dd, J = 2.1 Hz, 8.5 Hz, 1 H), 7.28 (d, J = 2.6 Hz 1 H), 7.12 (dd, J = 2.6 Hz, 8.9 
Hz, 1 H), 3.39 (broad s, 1 H), 2.67 (s, 3 H). 13C-NMR (150 MHz, DMSO-d6): δ = 169.6, 
163.1, 141.8, 141.5, 137.6, 137.4, 133.8, 133.0, 132.1, 131.6, 131.6, 131.4, 128.2, 127.7, 
126.1, 125.6, 122.2, 119.8, 118.3, 115.8, 19.7. MS (ESI) [M + H]+ m/z = 556.9.
Fluorescence Polarization Anisotropy (FPA) Assays
90,000 compounds from the Vanderbilt Institute of Chemical Biology compound collection 
were screened at the High Throughput Screening core at a single concentration of 30 mM 
for their ability to disrupt the binding of an ATRIP-based probe to RPA70N. The protocol is 
described in full detail in Souza-Fagundes, E.M., et al., Anal Biochem, 2012.14
FPA competition assays were conducted as previously described with minor 
modifications.12,14 Compounds were diluted in a 10-point, 3-fold serial dilution scheme in 
DMSO for a final concentration range of 500 – 0.025 µM. Compounds were added to assay 
buffer (50 mM HEPES, 75 mM NaCl, 5 mM DTT, pH 7.5) containing FITC-labeled probe 
and appropriate RPA70 protein in a final reaction volume of 50 µL containing 5% DMSO. 
All assays were conducted using a protein concentration equal to 1× Kd for the protein/probe 
interaction. Therefore, competition for binding to RPA70N was measured using either the 
FITC-ATRIP peptide (FITC-Ahx-DFTADDLEELDTLAS-NH2; 50 nM with 6 µM RPA70N) 
or the FITC-ATRIP2 peptide (FITC-Ahx-DFTADDLEEWFAL-NH2; 25 nM with 350 nM 
RPA70N). Binding to RPA70NAB was measured using 200 nM RPA70NAB and 25 nM 
FITC-ATRIP2. Following incubation for 1h, emission anisotropy was measured using the 
EnVision plate reader (Perkin Elmer). IC50 values were generated using a four-parameter 
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dose-response (variable slope) equation in XLfit and were converted to Kd values. Reported 
Kd values are the average of two independent experiments, run in duplicate.
X-ray crystal structures of complexes with RPA70N—Crystals of the E7R mutant of 
RPA70N were grown as described previously.20 X-ray diffraction data were collected at 
sector 21 (Life Sciences Collaborative Access Team, LS-CAT) of the Advanced Photon 
Source (Argonne, IL). All data were processed by HKL-2000.22 E7R crystallized in space 
group P212121 and contained one molecule in the asymmetric unit. Initial phases were 
obtained by molecular replacement with PHASER23 using the structure of the free protein 
(4IPC) as a search model. Iterative cycles of model building and refinement were performed 
using COOT24 and PHENIX.25 The structure of compound 20c bound to E7R are deposited 
at the Protein Data Bank under accession code 5E7N. The program Pymol (Schrödinger) 
was used to visualize and analyze the structures.
Protein Binding and Cellular Permeability Studies—The studies on 20c were 
performed by Absorption Systems, a preclinical contract research organization. Brief details 
of the studies can be could in the Supplementary Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Previously reported RPA PPI inhibitors.
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Selected HTS hit compounds.
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A) Compound 11 in complex with RPA70N. B) Compound 11 in complex with RPA70N 
with p53 peptide18 superimposed. C) Compound 11 in complex with RPA70N with 
compounds 4 and 5 superimposed. D) SAR strategy for compound 11.
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General synthesis of anthranilic acid-based RPA inhibitors. Reagents and conditions: a) 
Chlorosulfonic acid, reflux, 16 hrs; b) thionyl chloride, 75°C, 4 hrs; c) methyl 2-
aminobenzoate-R2, THF, 12 hrs d) aniline-R1, toluene, 70°C, 12hrs; e) 2M LiOH, 55°C, 2 
hrs.
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Table 1
Structure activity relationships in Site-1.
Compd R1 Kd (µM)[a] LE[c]
11 4-Br 30±6 0.21
12 H 156 ± 11 0.18
13 3-Me 165 ± 34 0.18
14 4-Me 196 0.17
15 4-OMe 234 ± 3 0.16
16 4-ethyl 95 ± 6.5 0.18
17 4-isopropyl 76 ± 5.5 0.17
18 3-Cl 29 ± 2 0.21
19 4-Cl 44 ± 0 0.20
20 3,4-diCl 7 ± 3 0.23
21 3,4-diMe 150 ± 11 0.17
22 3-Cl, 4-Me 43 ± 3.5 0.19
23 3-Me, 4-Cl 58 ± 11 0.18
24 2-naphthyl[b] 83 ± 8 0.17
25 3',4'-dichloro-[1,1'-biphenyl]-3-amine[b] 4 ± 0.5 0.20
26 indane[b] 106 ± 5.5 0.17
27 cyclopentyl[b] >250 0.18
28 cyclohexyl[b] 193 0.18
29 4-aminotetrahydropyran[b] >250 n.c. [d]
30 cycloheptyl[b] 110 ± 4 0.19
31 trans-4-Me cyclohexyl[b] 81 ± 10 0.20
32 cyclohexylmethyl[b] 126 ± 1 0.19
33 benzyl[b] >250 n.c.[d]
34 azepane[b] 208 0.18
35 octahydrocyclopenta[c]pyrrole[b] 222 ± 28 0.17
36 isoindoline[b] >250 n.c. [d]
[a]
Average Kd values (n=2) calculated using Cheng-Prusoff equation from IC50 values measured in FPA competition assay.
[b]
Entire ring system replaces the phenyl.
[c]
LE values calculated using LE = 1.4*pKd/HAC, using the FPA data.
[d]
n.c. = not calculated.
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